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Abstract
Negative symptoms are present in the psychosis prodrome. However, the extent to which these
symptoms are present prior to the onset of the first episode of psychosis remains under-researched.
The goal of this study is to examine negative symptoms in a sample of individuals at clinical high
risk (CHR) for psychosis and to determine if they are predictive of conversion to psychosis.
Participants (n=138) were all participants in the North American Prodrome Longitudinal Study
(NAPLS 1) project. Negative symptoms were assessed longitudinally using the Scale of
Prodromal Symptoms. The mean total negative symptom score at baseline was 11.0, with 82.0%
of the sample scoring at moderate severity or above on at least one negative symptom. Over the
course of 12 months, the symptoms remained in the above moderate severity range for 54.0% of
participants. Associations between individual symptoms were moderate (r= 0.31 to r= 0.57,
P<0.001) and a factor analysis confirmed that all negative symptoms loaded heavily on one factor.
Negative symptoms were more severe and persistent over-time in those who converted to
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psychosis, predicting the likelihood of conversion (χ2 = 17.63, df= 6, P< 0.01, R2 = 0.21). Thus,
early and persistent negative symptoms may represent a vulnerability for risk of developing
psychosis.
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psychosis prodrome; negative symptoms; conversion to psychosis; longitudinal study; NAPLS1
project
1. Introduction
Recent advances in research in early detection of psychosis have led to the development of
reliable criteria to identify individuals who may be at risk of developing psychosis and thus
potentially experiencing a prodrome for psychosis (Yung and McGorry, 1996b; McGlashan
et al., 2010). These prospective studies rely primarily on the presence of attenuated positive
symptoms and decreased functioning (Yung and McGorry, 1996b; McGlashan et al., 2010).
However, significant proportions of these individuals have non-specific symptoms (e.g.
depression and anxiety) as well as negative symptoms, such as social isolation/withdrawal,
and reduced motivation (Lencz et al., 2004). This finding pertaining to the construct of
amotivation or avolition is in agreement with findings from patients with schizophrenia
(Faerden et al., 2009). Interestingly it is these behavioural and functional changes that are
often the first reasons for seeking help (Yung and McGorry, 1996a; Lencz et al., 2004).
Relative to attenuated positive symptoms the prevalence of negative symptoms is high
(Yung et al., 2003; Lencz et al., 2004; Velthorst et al., 2009) of which social isolation and
deterioration in role (school) functioning are most frequently reported (Lencz et al., 2004).
Furthermore, negative symptoms, especially increased social isolation and withdrawal, have
been reported to be predictive of transition to psychosis (Kwapil, 1998; Mason et al., 2004;
Yung et al., 2005; Velthorst et al., 2009). In the Edinburgh longitudinal study of individuals
at genetic high risk of psychosis (Johnstone et al., 2005), social withdrawal and isolation, as
measured on the Structural Interview for Schizotypy, emerged as the strongest discriminator
between those who converted and those who did not.
Typically, negative symptoms are examined as one construct, although there are reports of
negative symptoms clustering into two domains of diminished expression (i.e. affective
flattening and poverty of speech) and amotivation (i.e. avolition/apathy and anhedonia/
asociality) (Mueser et al., 1994; Sayers et al., 1996). More recently there has been a focus on
differences among individual negative symptoms with suggestions that “avolition” is a core
negative symptom with a direct impact on both functional outcome and cognitive function
(Foussias and Remington, 2010).
Previous studies of the psychosis prodrome that explored the predictive value of negative
symptoms to psychosis conversion have done so using different instruments to assess
prodromal symptoms. Whereas some studies used scales designed to rate the severity of sub-
psychotic level symptoms (Yung et al., 2005; Velthorst et al., 2009) others used
conventional rating scales for psychotic-level symptoms (Mason et al., 2004) or a scale
designed to assess a single symptom (Kwapil, 1998). Furthermore, none of the studies
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included longitudinal examination of negative symptoms. Thus, the goal of the present
investigation was to examine in more detail negative symptoms in a sample of individuals
described as being at clinical high risk (CHR) of developing psychosis. The specific aims
were: 1) to determine the prevalence of individual negative symptoms; 2) to determine the
stability of negative symptoms, 3) to explore the factor structure of positive and negative




The North American Prodrome Longitudinal Study (NAPLS-1) project is a consortium of
eight research sites that investigated the earliest phase of psychotic illness, with the goal of
improving the accuracy of prospective prediction of psychosis (Addington et al., 2007;
Cannon et al., 2008). All sites recruited CHR individuals and followed them up for a period
of up to 2. years during the period 2000–2006. Although initially developed as independent
studies, the investigations at eight sites employed similar ascertainment and diagnostic
methods (Structured Interview for Prodromal Syndromes(SIPS) (McGlashan et al., 2010)
making it possible to form a standardised protocol for mapping data into a new scheme
representing the common components across sites (Addington et al., 2007). The study
protocols and informed consents were reviewed and approved by the ethical review boards
of all eight study sites. Methods and details of the NAPLS-1 are reviewed in detail
elsewhere (Addington et al., 2007; Cannon et al., 2008).
Three hundred and seventy-two participants met one of the three established criteria for a
psychosis risk syndrome, namely: attenuated psychotic symptom state (APSS), brief
intermittent psychotic symptom state (BIPS) and genetic risk with deterioration (GRD).
Criteria for a prodromal syndrome and criteria for conversion to psychosis were determined
using the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al., 2010).
Conversion meant that at least one of the five attenuated positive symptoms reached a
psychotic level of intensity (rated 6) for a frequency of ≥ 1 hour/day for 4 days/week during
the past month or that symptoms seriously impacting functioning (e.g. severely disorganised
or dangerous to self or others) (McGlashan et al., 2010). All NAPLS sites demonstrated
reliability in rating criteria (κ’s ranged from 0.80 to 1.00 across sites) (Addington et al.,
2007).
The Structured Clinical Interview for DSM-IV (SCID-I) (First et al., 1995) was used to
determine the presence of any axis I disorders. Participants were excluded if they met
criteria for any current or lifetime axis I psychotic disorder, IQ< than 70 or past or current
history of a clinically significant central nervous system disorder which may confound or
contribute to prodromal symptoms.
For this project we only included participants who had completed the negative symptom
ratings at both 6- and 12-month follow-up. Thus, participants were 50 females and 88 males.
At ascertainment, the mean age was 18.6 years (SD= 4.88). On average participants had 10.7
years of education (SD=3.25) with 91 participants (66.0%) attending high school and 18
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(13.0%) attending college. Twenty-six participants (19.0%) were employed full-time. Sixty-
six participants (48.0 %) met DSM-IV criteria for a mood disorder, 12 (9.0%) met criteria
for an anxiety disorder and 5 (3.5 %) met criteria for substance abuse disorders. All
participants met the criteria for attenuated psychotic symptom syndrome (APSS). This
sample of 138 did not differ on demographic or symptom variables from the 234 participants
excluded from the analysis who did not have follow-up data on negative symptoms.
2.2. Assessments
The Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al., 2010) criteria
were used at the study entry. Attenuated positive symptoms and negative symptoms were
assessed using the Scale of Prodromal Symptoms (SOPS)1.
2.3. Statistical Analyses
Demographic variables and negative symptom ratings were summarised using descriptive
statistics. Difference in prevalence of negative symptoms over time was assessed using the
two-proportions Z-test. Stability of negative symptoms over time was assessed using
repeated measures ANOVA with the Bonferroni correction for multiple comparisons.
Principal component analysis (PCA) was used to explore the factor structure of positive and
negative symptoms of the SOPS. Participants who received a diagnosis of a psychotic
disorder during the course of the study were classified as converters. Group differences
between converters and non-converters, as well as gender differences, were assessed using
the Mann-Whitney U test (MWU). Direct logistic regression was performed to evaluate the
predictive value of negative symptoms on conversion. This method was chosen because it
allows evaluation of the contribution made by each negative symptom over and above
contribution of other predictors (Tabachnik and Fidel, 2001). Furthermore, it was an
appropriate model given that we had no specific hypotheses about the order or importance of
individual negative symptoms. All assumptions for the different analysis were met prior to
interpretation of the results.
3. Results
3.1. Baseline negative symptoms
A majority of participants (82.0%) at the start of the study endorsed at least one negative
symptom rated ≥ 3 on the SOPS (i.e. moderate to above moderate severity). Sixty-one
(44.0%) participants reported at least one symptom in the moderate to above moderate range
(i.e. SOPS ratings of 3 and 4), and 52 (38.0%) participants reported symptoms in the severe
range (i.e. SOPS ratings of 5 and 6). Males had more severe negative symptoms (M = 13.60,
SD= 7.25) compared to females (M = 8.86, SD= 6.58, t = −3.81, P< 0.001). Reported
prevalence for specific negative symptoms of ≥ 3 severity rating at baseline 6- and 12-month
follow-up are displayed in Figure 1. At baseline, “deterioration in role functioning”,
“avolition” and “social withdrawal” were the most frequently reported negative symptoms
whereas “decreased ideational richness” was the least reported symptom.
Descriptions of negative symptoms are available in the Supplementary Material
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3.2. Change over time
Repeated measures ANOVAs revealed that there was a significant decrease in severity of
negative symptoms over time (F (2, 274) = 43.72, P< 0.001). Table 1 displays the results of
within-subjects contrasts for changes in the severity of each negative symptom over time. At
12 months, seventy-four participants (54%) continued to score in the moderate to above
moderate severity (i.e. ≥ 3) on at least one negative symptom. Significant decrease in
prevalence of symptoms in the moderate to above moderate severity continued through the
follow-up period for some, but not all symptoms (Figure 1). For 39 participants, at least one
negative symptom was in the moderate and severe range both at baseline and the follow-up.
Among this group 11 participants were converters.
3.3. Factor loading and correlations between negative symptoms
All positive and negative symptoms of the SOPS were entered into a principal component
analysis. According to the correlation matrix, associations between individual negative
symptoms were moderate, with correlation coefficients ranging between r = 0.31 and r =
0.57 (P<0.001). Analyses of the factor extraction matrix and the scree plot indicated four
components with eigenvalues exceeding one. All negative symptom items loaded heavily on
the first component whereas positive symptoms were spread over the second, third and
fourth components. Furthermore, components three and four were similar in terms of
eigenvalues suggesting that retention of three components is justifiable. Following varimax
rotation of three components, all negative symptoms within the SOPS loaded on Factor 1.
See Table 2.
3.4. Conversion to psychosis
By 12 months, 20 (15.0%) participants, 5 females and 15 males, converted to psychosis.
Compared to participants who did not convert, converters had significantly higher severity
of negative symptoms at baseline (see Table 3). However, the two groups did not differ on
positive symptoms or any demographic variables, such as age, gender, ethnicity, years of
education or employment status.
Since both groups differed significantly on all six negative symptoms at baseline, all six
symptoms were entered into a direct logistic regression as possible predictors of conversion.
A test of the model with all six negative symptoms as predictors against an intercept only
model was statistically significant (χ2 = 14.64, df = 6, P< 0.05, Cox and Snell R2 = 0.10)
indicating that negative symptoms discriminated between participants who converted to
psychosis and those who did not. Assumptions of co-linearity (tolerance range: 0.51 to 0.79;
VIF range: 1.26 to 1.95) and goodness of fit (Hosmer-Lemeshow χ2 = 5.84, df = 8, P = 0.66)
were satisfied. No individual negative symptom emerged as a significant predictor of
conversion. The model explained 10% of variance in conversion rates.
Since negative symptoms persisted in a sub-group of participants over time we examined
whether those with persistent negative symptoms differed in rates of conversion from those
who had a decrease in negative symptoms. Using chi-square we compared the number of
converters in two groups, those with and those without persistent negative symptoms at 12
months. The analysis revealed that in the group of participants with persistent negative
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symptoms (n = 74) 17 converted to psychosis compared to only 3 participants in the group
without persistent negative symptoms (n = 64). This difference in the number of converters
in the two groups was significant (χ2 = 9.26, p< 0.01).
Thus, to determine if persistent negative symptoms were perhaps more likely to predict
conversion in a sub group with persistent negative symptoms (n = 74), all 6 negative
symptoms at 12 months were entered together into a logistic regression model against an
intercept only model. The model was statistically significant (χ2 = 17.63, df = 6, P< 0.01,
Cox and Snell R2 = 0.21) indicating that persistence of negative symptoms at 12 months
explained 21% of variance in the conversion rates in those with persistent negative
symptoms. However, no individual negative symptom emerged as a significant predictor of
conversion. Once again, assumptions of co linearity (tolerance range: 0.53 to 0.67; VIF
range: 1.50 to 1.90) and goodness of fit (Hosmer-Lemeshow χ2 = 12.28, df = 8, P = 0.12)
were satisfied.
3.5. Medication
The impact of antipsychotics on negative symptoms at baseline and 12 months was
examined using the non-parametric Mann-Whitney U test. At baseline, n= 8 were receiving
antipsychotics compared to n= 60 who were not. When the two groups were compared, the
analysis revealed no significant group differences at baseline, but significant group
differences at 12 months. That is, those receiving antipsychotics at 12 months demonstrated
higher severity of negative symptoms (n= 20; M = 10.30, SD = 6.77) compared to
participants who were not on antipsychotics (n= 51; M = 6.29, SD = 7.14, MWU = 299.50,
P< 0.01).
4. Discussion
In the current investigation, negative symptoms were prevalent at study admission in a
majority of CHR individuals, with males having more severe symptoms than females. A
majority of participants reported at least one negative symptom of moderate or high severity.
The most frequently endorsed symptoms of at least moderate severity were “deterioration in
role functioning”, “avolition” and “social withdrawal”, whereas the least frequently
endorsed symptoms were “diminution in affective experiences” and “decreased ideational
richness”. On average all of the significant improvement in negative symptoms occurred in
the first 6 months. However, a subgroup of participants continued to endorse individual
negative symptoms in the moderate to high severity range at follow-up. Thus, there appears
to be a subsample of CHR participants for whom significant negative symptoms persist over
the time period of this study. This observation has been reported in other high risk samples
as well as those at the first episode and with a more established schizophrenia illness
(Addington et al., 2003; Yung et al., 2003; Lencz et al., 2004; Yung et al., 2004; Blanchard
et al., 2005, Velthorst et al., 2009). With respect to the observed improvements, it is possible
that they reflect, at least to an extent, heterogeneity of the CHR sample which was evident in
an earlier publication of this sample (Addington et al., 2011). Here it was suggested that
CHR individuals represent a collection of individuals who tend to fall in the following
groups: 1) those truly at risk for psychosis that are showing the first signs of disorder; 2)
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those who remit in terms of the symptoms used to index CHR status, and 3) those who
continue to have attenuated symptoms of psychosis. Although there was evidence of apathy/
avolition in these CHR individuals it did not stand out as a possible core negative symptom
as has been described in samples with a more established psychotic illness (Faerden et al.,
2009). In fact, our data supports the emergence of a distinct negative symptom factor, which
fits with a previous report from a smaller sample of CHR participants (Hawkins et al.,
2004).
Those who went on to develop a full blown psychotic illness had significantly more severe
baseline negative symptoms, in particular “deterioration in role functioning” and “social
withdrawal”, which persisted over a 12 month period in a subgroup of participants.
Although, baseline negative symptoms predicted conversion, persistence of symptoms over
12 months was a better predictor of conversion than severity of baseline symptoms alone.
Despite the fact that stability of negative symptoms explained one fifth of the variance in
conversion rates, it is possible that other factors, such as psychosocial functioning, make a
larger contribution to conversion (Cornblatt et al., in press). It was noted that those on
antipsychotics had higher levels of negative symptoms. It cannot be determined if this is due
to secondary effects of antipsychotic medication or simply to the possibility that individuals
with more severe symptoms overall are the ones for whom the antipsychotics are prescribed.
The main strengths of this study are its longitudinal, prospective design, large sample size of
CHR individuals and examination of the SOPS factor structure. There are some limitations.
First, the follow-up period is short. A second limitation is that negative symptoms were
rated on the negative symptom subscale of the SOPS. To the best of our knowledge we are
not aware of any research that has compared the ratings of negative symptoms on the SOPS
to rating negative symptoms on scales used for those with established psychotic illness such
as the PANSS and the SANS. It is unknown if negative symptoms rated on the SOPS differ
from negative symptoms rated on one of these other scales. Future work needs to examine
the relationship of SOPS negative symptom ratings to ratings on more established scales of
negative symptoms. A further concern is that N6 clearly reflects poor functioning. This
would be an important area for future research particularly in light of the recent work by the
NIMH task force on negative symptoms (Blanchard and Cohen, 2006; Kirkpatrick et al.,
2006).
In conclusion, the current study finds that moderate and severe attenuated negative
symptoms are frequently endorsed by individuals at CHR of psychosis, and all contribute to
a broad single negative symptom factor. Although the severity of negative symptoms is
higher at study entry and dissipates over time, there appears to be a subsample of CHR
individuals for whom “deterioration in role functioning”, “avolition” and “social
withdrawal” persist over a longer course. Negative symptoms are more severe and persistent
in individuals who convert to psychosis, and are moderately predictive of later conversion.
In conclusion, it may be that attenuated negative symptoms represent a core vulnerability
placing individuals at clinical high risk of developing psychosis, and could be important
targets of early intervention.
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Prevalence of reported negative symptoms rated ≥ 3 at baseline, 6 and 12 months
Note: a, significantly different from baseline at P<0.05 level
b, significantly different from 6-months at P<0.05 level
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Table 1








N1- social isolation/withdrawal 2.54 (1.95) 1.72 (1.81)a 1.90 (1.91)a <0.001
N2- avolition 2.51 (1.64) 1.56 (1.69)a 1.74 (1.71)a <0.001
N3- decreased expression of emotion 1.37 (1.64) 0.98 (1.38)a 1.02 (1.40) <0.01
N4- decreased experience of emotion 1.41 (4.65) 0.88 (1.40)a 0.72 (1.20)a <0.001
N5- decreased ideational richness 1.01 (1.37) 0.70 (1.20)a 0.69 (1.23)a <0.01
N6- deterioration in role functioning 3.04 (1.92) 1.79 (1.86)a 1.74 (1.96)a <0.001
N_total 11.88 (7.36) 7.62 (7.20)a 7.81 (7.14)a <0.001
Note:
a
significantly different from baseline at P< 0.01 after the Bonferroni correction for multiple comparisons
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Table 2





N6- Deterioration in role functioning .763
N3- Decreased expression of emotion .726
N1- Social isolation and withdrawal .688 .379
N4- Decreased experience of emotion and self .657
N5- Decreased ideational richness .618 .357
P1- Unusual thought content/delusional ideas .728
P2- Suspiciousness/persecutory ideas .575
P3- Grandiosity .708
P4- Perceptual abnormalities/hallucinations .563 −.636
P5- Conceptual disorganization .516
Extraction Method: Principal Component Analysis with varimax rotation.
Primary loadings are displayed in bold typeface. Loadings < 0.35 are omitted from the table for clarity
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Table 3










N1- Avolition 2.36 (1.91) 3.60 (1.90) 760.0 <0.05
N2- Social isolation and withdrawal 2.36 (1.62) 3.35 (1.56) 810.5 <0.05
N3- Decreased expression of emotion 1.24 (1.57) 2.15 (1.87) 846.0 <0.05
N4- Decreased experience of emotion and self 1.29 (1.62) 2.15 (1.69) 851.5 <0.05
N5- Decreased ideational richness 0.86 (1.24) 1.95 (1.76) 762.5 <0.05
N6- Deterioration in role functioning 2.86 (1.91) 4.10 (1.68) 749.0 <0.001
Total negative symptoms 10.97 (6.89) 17.30 (7.87) 656.0 <0.01
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